Compare ACADIA Pharmaceuticals Inc. (ACAD) vs iShares Self-Driving EV and Tech (IDRV) Price & Performance

ACADIA Pharmaceuticals (ACAD) trades at $29.47, up 0.26% with strong technical momentum and bullish moving average signals. The company reported robust Q2 2026 earnings of $0.18 per share, beating estimates by 164%, driven by strong Daybue and Nuplazid sales. Revenue reached $1.07 billion in 2025 with impressive net income margins of 33.42%. Recent FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis adds to positive catalysts.

ACAD presents compelling growth potential with 70% analyst buy ratings and a $33.89 consensus price target implying 15% upside. Strong revenue growth trajectory and expanding profitability support bullish case, though elevated EV/EBITDA of 42.55 and recent RSI overbought signals warrant caution. Key risk remains clinical trial outcomes for pipeline assets.

IDRV trades at $37.18, down 0.51% today, with a bullish technical signal from moving averages and key indicators like the ADX suggesting a strong trend. Support levels are firm near $35–$37, while resistance sits at $38–$39. Recent news highlights rising global EV sales, with growth in Europe and China, though U.S. adoption lags. The company has a dividend scheduled for June 2026.

The outlook for IDRV is cautiously optimistic, driven by sector tailwinds from EV adoption and regulatory support. Key risks include competitive pressures from Chinese automakers and sensitivity to fuel price volatility. Analyst sentiment is mixed, with technical strength offset by fundamental data gaps. Investors should monitor upcoming earnings for margin trends and guidance updates.